Just a year after the first AI-designed protein was made, scientists are preparing for clinical trials testing AI-designed ...
Teclistamab-cqyv plus subcutaneous daratumumab significantly improved OS and PFS in relapsed/refractory multiple myeloma compared to standard regimens, reducing death risk by 54%. The combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback